3627 related articles for article (PubMed ID: 7533669)
1. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Smith KS; Folz BA; Adams EG; Bhuyan BK
Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669
[TBL] [Abstract][Full Text] [Related]
2. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP
Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
Côté S; Momparler RL
Anticancer Drugs; 1993 Jun; 4(3):327-33. PubMed ID: 7689364
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin.
Bhuyan BK; Smith KS; Kelly RC; Adams EG; Abraham I; Sampson KE
Cancer Res; 1993 Mar; 53(6):1354-9. PubMed ID: 8443816
[TBL] [Abstract][Full Text] [Related]
5. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.
Li LH; Kelly RC; Warpehoski MA; McGovren JP; Gebhard I; DeKoning TF
Invest New Drugs; 1991 May; 9(2):137-48. PubMed ID: 1874598
[TBL] [Abstract][Full Text] [Related]
6. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.
Bhuyan BK; Smith KS; Adams EG; Wallace TL; Von Hoff DD; Li LH
Cancer Chemother Pharmacol; 1992; 30(5):348-54. PubMed ID: 1505072
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
Foster BJ; LoRusso PM; Poplin E; Zalupski M; Valdivieso M; Wozniak A; Flaherty L; Kasunic DA; Earhart RH; Baker LH
Invest New Drugs; 1996; 13(4):321-6. PubMed ID: 8824350
[TBL] [Abstract][Full Text] [Related]
8. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection.
Yanow SK; Purcell LA; Spithill TW
Mol Biochem Parasitol; 2006 Jul; 148(1):52-9. PubMed ID: 16597469
[TBL] [Abstract][Full Text] [Related]
9. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
10. Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.
Abbruzzese JL; Frost P
Cancer Chemother Pharmacol; 1992; 30(1):31-6. PubMed ID: 1375133
[TBL] [Abstract][Full Text] [Related]
11. Sequence selectivity of DNA alkylation by adozelesin and carzelesin.
Yoon JH; Lee CS
Arch Pharm Res; 1998 Aug; 21(4):385-90. PubMed ID: 9875464
[TBL] [Abstract][Full Text] [Related]
12. Determination of the structural role of the linking moieties in the DNA binding of adozelesin.
Cameron L; Thompson AS
Biochemistry; 2000 May; 39(17):5004-12. PubMed ID: 10819964
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Mar; 10(3):295-302. PubMed ID: 10327036
[TBL] [Abstract][Full Text] [Related]
14. Excision repair of adozelesin-N3 adenine adduct by 3-methyladenine-DNA glycosylases and UvrABC nuclease.
Jin SG; Choi JH; Ahn B; O'Connor TR; Mar W; Lee CS
Mol Cells; 2001 Feb; 11(1):41-7. PubMed ID: 11266119
[TBL] [Abstract][Full Text] [Related]
15. Phase I study with the DNA sequence-specific agent adozelesin.
Burris HA; Dieras VC; Tunca M; Earhart RH; Eckardt JR; Rodriguez GI; Shaffer DS; Fields SM; Campbell E; Schaaf L; Kasunic D; Von Hoff DD
Anticancer Drugs; 1997 Jul; 8(6):588-96. PubMed ID: 9300573
[TBL] [Abstract][Full Text] [Related]
16. Induction of DNA damage responses by adozelesin is S phase-specific and dependent on active replication forks.
Liu JS; Kuo SR; Beerman TA; Melendy T
Mol Cancer Ther; 2003 Jan; 2(1):41-7. PubMed ID: 12533671
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
Fleming GF; Ratain MJ; O'Brien SM; Schilsky RL; Hoffman PC; Richards JM; Vogelzang NJ; Kasunic DA; Earhart RH
J Natl Cancer Inst; 1994 Mar; 86(5):368-72. PubMed ID: 8308929
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.
Nguyen HN; Sevin BU; Averette H; Perras J; Hightower R; Ramos R; Donato D; Penalver M
Cancer Chemother Pharmacol; 1992; 30(1):37-42. PubMed ID: 1586978
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
